This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Thymosin Alpha 1
Tα1 is a 28-amino-acid synthetic peptide identical to the natural thymic hormone — an immune modulator (not stimulator, not suppressor) that re-polarizes the T-cell / NK / dendritic-cell axis towar…
Aliases (8)
Overview
What is Thymosin Alpha 1?
Thymosin alpha-1 (Tα1, Zadaxin) is a 28-amino-acid synthetic peptide identical to a naturally occurring thymic hormone. It is approved in 35+ countries for hepatitis B, hepatitis C, and as an immune-enhancing adjunct in cancer and infections; in the US it remains a research-use peptide.
Key Benefits
Boosts adaptive immune response (enhances T-cell maturation and function), useful in chronic viral infections (HBV, HCV), cancer adjunct therapy, and immunosenescence in aging. May also reduce inflammatory cytokines in autoimmune conditions.
Mechanism of Action
Binds Toll-like receptors (primarily TLR9) on dendritic cells and other immune cells, enhancing maturation and antigen presentation. This drives T-helper-1 (Th1) immune polarization, increases natural killer cell activity, and supports thymopoiesis (T-cell maturation).
Pharmacokinetics
Research Indications
Primary Immunodeficiencies
FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence.
Vaccine Response Enhancement
Enhances immunogenicity in elderly and immunocompromised patients with improved antibody responses.
HIV/AIDS Immune Support
Restores CD4+ T-cell counts and reduces opportunistic infections with sustained immunological improvement.
Cytokine Storm Mitigation
Reduces pro-inflammatory cytokines by 40-60% while maintaining balanced immune responses.
Chronic Inflammatory Conditions
Modulates inflammatory responses in hepatitis, pancreatitis, and autoimmune conditions.
Post-Surgical Immune Recovery
Accelerates immune system recovery following major surgery or chemotherapy through lymphocyte restoration.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Documented synergistic NK cell activation in chronic viral hepatitis. Not relevant for users in this archetype unless he develops chronic HBV/HCV — flagging …
Tα1 enhances vaccine immunogenicity in elderly and immunocompromised. Could be relevant: if the user gets a flu shot or future COVID booster during a heavy-l…
Mechanism-additive, established clinical use. Not relevant for users in this archetype.
(already in V4) — antioxidant and immune-cofactor infrastructure that Tα1 operates on top of. Clean adjuncts.
Mechanism-additive — supports cellular redox during immune challenge. Listed as related-slug in pep-pedia.
Mechanism-additive (zinc is immune cofactor); strong stand-alone evidence for cold duration.
Absolute contraindication. Mechanism-opposing; documented harm in transplant patients (fatal immune hemolytic anemia, graft rejection).
Pharmacodynamic antagonism — Tα1 blocks steroid-induced thymocyte apoptosis, partially neutralizing immunosuppressive effect of steroids. Not relevant for us…
Mechanism-opposing. Not relevant for users in this archetype.
Absolute contraindication in organ transplant recipients. Fatal immune hemolytic anemia and graft rejection documented in hematopoietic stem cell transplant patients.
Pharmacodynamic antagonism as Ta1 blocks steroid-induced thymocyte apoptosis, potentially reducing immunosuppressive effects.
Enhanced antiviral efficacy in hepatitis treatment with synergistic NK cell activation. Monitor for increased fever, fatigue, and neutropenia.
Intended therapeutic effect enhancing vaccine immunogenicity, particularly beneficial in elderly and immunocompromised patients.
Protective effects against cytotoxic bone marrow damage while maintaining standard oncology monitoring protocols.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 7
Side Effects
- 1Mild injection-site reaction (redness, small welt, transient soreness) — self-limiting <24 h, the most common side effect
- 2Transient mild fatigue in 2-12 h post-injection during first 1-2 doses (immune system "waking up"; resolves with continued dosing)
- 3Mild transient flu-like feeling in some users on first 1-2 doses (low-grade malaise, mild myalgia) — interpretable as immune-activation signal, not adverse
- 4Mild headache (transient, hours)
- 5Mild nausea or lightheadedness (especially first dose)
- 6Sleep architecture changes — minority report mild sleep-onset issues in first week, generally resolves
- 7Slight feverish sensation (low-grade subjective warmth without measurable fever)
When to Stop
- Fatal immune hemolytic anemia + graft rejection in hematopoietic stem cell transplant patients. Documented case reports — Tα1 is absolutely contraindicated in organ transplant recipients receiving immunosuppressive therapy. The peptide drives immune activation that opposes the transplant-tolerance state, with potentially fatal consequences. Not relevant for users in this archetype but critical to flag for any clinician using Tα1.
- Local injection-site allergic reaction. Very rare; theoretical anaphylaxis with first dose. Standard first-injection precaution: at home, antihistamine (diphenhydramine 25-50 mg) accessible, someone within earshot, no driving / training in first 30 minutes post-first-injection.
- Immune over-activation in autoimmune disease. Theoretical. No published case reports of Tα1 worsening autoimmune flares (lupus, RA, MS, Hashimoto's), but caution warranted in active autoimmune disease — Th1 polarization could in theory worsen Th1-mediated autoimmunity.
- Day 1 + first 30 min of any new use: low anaphylaxis risk but standard precaution. Inject at home, antihistamine within reach.
- First 2 doses: monitor for transient flu-like feeling — this is normal-to-expected, not adverse, but lets you know the peptide is bioactive.
- Throughout PRN cycles: track illness duration, symptom-resolution time, energy recovery — these are the relevant subjective endpoints.
- Active organ transplant recipients on immunosuppression (absolute — cyclosporine, tacrolimus, mycophenolate, post-transplant biologics)
- Active untreated autoimmune disease in flare (relative — discuss with rheumatologist)
- Pregnancy / lactation (no human data; theoretical)
- Known peptide hypersensitivity
References
Thymosin Alpha 1 Wikipedia
synthetic 28-AA peptide structure, history, Zadaxin brand, regulatory status across countries
View StudyComprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials (Dinetz & Lee 2024, *Alternative Therapies in Health and Medicine*, PubMed 38308608)
meta-review across 11,000+ patients, 30+ trials, <1% serious AEs
View StudyEfficacy and Safety of Thymosin α1 for Sepsis (TESTS): Multicentre RCT Phase 3 (Zhang 2025, *BMJ*)
definitive Phase 3 negative for primary endpoint (1,106 patients)
View StudyThymosin Alpha 1 in Severe Acute Pancreatitis Meta-Analysis (Tian 2025, *Frontiers in Immunology*)
706 patients, significant infection rate + inflammation reduction
View StudyA Pilot Trial of Thymalfasin in Hospitalized COVID-19 Patients (Shehadeh 2023, *Journal of Infectious Diseases*)
improved lymphocyte recovery, mixed clinical outcomes
View StudyTα1 Reduces Mortality of Severe COVID-19 by Restoration of Lymphocytopenia (Liu 2020, *Clinical Infectious Diseases*)
retrospective trial, 30% → 11% mortality reduction
View StudyTα1 Restores Immune Homeostasis in Lymphocytes During PASC (Romano 2023, *Frontiers in Immunology*)
Long COVID immune restoration, 1.6 mg SC 2x/week × 12 weeks
View StudyTα1 Mitigates Cytokine Storm in COVID-19 Blood Cells (Garaci 2021, *Frontiers in Immunology*)
40-60% reduction in TNF-α, IL-1β, IL-6
View StudyTα1: A Comprehensive Review of the Literature (Dominari 2020, *World Journal of Virology*)
narrative review covering mechanism + indications
View StudyEfficacy of Tα1 for Severe Sepsis (ETASS) — Multicenter Single-Blind RCT (Wu 2013, *Critical Care*, PMC4056079)
original positive sepsis trial, basis for TESTS
View StudyImmune Modulation with Tα1 Treatment (King & Tuthill 2016, *Vitamins and Hormones*)
mechanism review covering TLR9/TLR2 + Th1 polarization
View StudyTESTS Phase 3 Sepsis Trial Registration (NCT02867267)
clinical trial registration for largest Tα1 RCT
View StudyPep-pedia Thymosin Alpha 1 entry
structured data overview, dosing protocols, indications by category
View StudyCastell Sports Immunology / Open Window Theory references
foundational sport-immunology literature behind Tα1 athletic-immune-support extrapolation
View StudyWADA 2026 Prohibited List (PDF, official)
verify Tα1 status annually before any competition use
View StudyLimitless Life Nootropics Tα1 product page
gray-market sourcing reference
View StudyPharma Lab Global Tα1 product page
international gray-market sourcing reference
View StudySciClone / Sigma-Tau Zadaxin product information
brand-name pharmaceutical reference (35+ country approvals)
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.